In real-world clinical practice, Ocrevus (ocrelizumab) showed sustained effectiveness in people with relapsing forms of multiple sclerosis (MS), with most patients remaining free from long-term worsening of disability over four years, according to a new study. Relapse rates and MRI disease activity were also low during follow-up. At four years, 39.7% of patients with available […]
The post New real-world study supports long-term Ocrevus use in relapsing MS appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com